Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681258 | 0.78 | GABRA1 (0.64) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL20816450 | 0.76 | GABRA1 (0.50) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL13993252 | 0.76 | GABRA1 (0.61) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL22899728 | 0.76 | GABRA1 (0.61) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL3640323 | 0.74 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL4713540 | 0.74 | GABRA1 (0.52) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL22774086 | 0.74 | GABRA1 (0.58) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL636376 | 0.74 | GABRA1 (0.58) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL3979806 | 0.73 | GABRA1 (0.46) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL31370930 | 0.73 | GABRA1 (0.46) | GABRA1GABRB1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| EP-3569606-B1 | METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO (1,2-F)PHENANTHRIDINE AND DIIMIDAZO (1,2-A; 1', 2'-C)QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF | UNIVERSAL DISPLAY CORP (US) | 2022-01-05 | — | — | EP | disclosed |
| US-7915415-B2 | Metal complexes of cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2243785-A1 | Phosphorescent condensed ring carbene metal complexes for use in organic light emitting devices | Universal Display Corporation (US) | 2010-10-27 | — | — | EP | disclosed |
| CN-101415718-A | Cyclometallated imidazo [1 ] s | UNIVERSAL DISPLAY CORP (US) | 2009-04-22 | — | — | CN | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| EP-1981898-A2 | METAL COMPLEXES OF CYCLOMETALLATED IMIDAZOÝ1,2-f¨PHENANTHRIDINE AND DIIMIDAZOÝ1,2-A:1',2'-C¨QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF | Universal Display Corporation (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007095118-A2 | METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF | UNIVERSAL DISPLAY CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070190359-A1 | Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070190359-A1 | Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070190359-A1 | Metal complexes of cyclometallated imidazo[1,2-ƒ]phenanthridine and diimidazo[1,2-a:1',2'-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GABRA1 3978/4885GABRB1 3579/4885GABRB2 3571/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | GABRA1 3418/4885GABRB1 3415/4885GABRB2 3808/4885 |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | GABRA1 432/4885GABRB1 1628/4885GABRB2 1574/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GABRA1 3978/4885GABRB1 3579/4885GABRB2 3571/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GABRA1 3753/4885GABRB1 3231/4885GABRB2 3267/4885 |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | GABRA1 4862/4885GABRB1 4791/4885GABRB2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.